{"hands_on_practices": [{"introduction": "The Plaque Reduction Neutralization Test (PRNT) is a gold-standard functional assay in virology for quantifying the potency of neutralizing antibodies. This exercise provides a practical application of the core principles behind this assay, starting from a common experimental endpoint where a serial dilution causes a fractional plaque reduction of $0.5$. You will translate this dilution factor into a standardized $\\text{PRNT}_{50}$ titer, a fundamental skill for interpreting serological data and comparing antibody responses. [@problem_id:2832663]", "problem": "A laboratory uses the Plaque Reduction Neutralization Test (PRNT) to quantify antibody-mediated neutralization of a cytopathic virus by patient sera. In PRNT, a virus-only control yields a baseline plaque count denoted $P_{0}$, and a serum at dilution factor $d$ (expressed as a fraction of the undiluted serum, so that $d = 1/320$ for a $1{:}320$ dilution) yields a plaque count $P(d)$. The observed neutralization at dilution $d$ is defined as the fractional reduction in plaques relative to control, $R(d) = 1 - P(d)/P_0$. The $\\text{PRNT}_{50}$ titer is defined as the reciprocal of the dilution factor that produces $R(d) = 0.5$ under otherwise identical assay conditions.\n\nA sample of Serum A produces, by interpolation across a two-fold serial dilution series, exactly $50\\%$ plaque reduction at a dilution of $1{:}320$. A second sample, Serum B, produces exactly $50\\%$ plaque reduction at a dilution of $1{:}40$. Assume both sera were tested side-by-side in the same assay run so that comparisons across sera are valid.\n\nUsing the core definition of $\\text{PRNT}_{50}$ titer and first principles of dilution, (i) determine the $\\text{PRNT}_{50}$ titer for Serum A, and (ii) derive how to compare neutralizing activity across sera using titers. Then compute the fold difference in neutralization potency defined as the ratio of the $\\text{PRNT}_{50}$ titer of Serum A to that of Serum B.\n\nExpress your final answer as a pure number (no units), rounded to three significant figures. Report only the fold-difference as your final numeric answer.", "solution": "The problem as stated is subjected to validation.\n\nStep 1: Extracted Givens\n-   Baseline plaque count (virus-only control): $P_0$\n-   Plaque count at dilution factor $d$: $P(d)$\n-   Dilution factor $d$: a fraction of the undiluted serum, e.g., $d = \\frac{1}{320}$ for a $1{:}320$ dilution.\n-   Observed neutralization at dilution $d$: $R(d) = 1 - \\frac{P(d)}{P_0}$\n-   $\\text{PRNT}_{50}$ titer: defined as the reciprocal of the dilution factor $d$ that produces $R(d) = 0.5$.\n-   Serum A: achieves $50\\%$ plaque reduction ($R(d) = 0.5$) at a dilution of $1{:}320$.\n-   Serum B: achieves $50\\%$ plaque reduction ($R(d) = 0.5$) at a dilution of $1{:}40$.\n-   Assumption: The sera were tested in the same assay run, validating direct comparison.\n-   Task (i): Determine the $\\text{PRNT}_{50}$ titer for Serum A.\n-   Task (ii): Derive the principle for comparing neutralizing activity using titers.\n-   Task (iii): Compute the fold difference in neutralization potency, defined as the ratio of the $\\text{PRNT}_{50}$ titer of Serum A to that of Serum B.\n-   Final Answer: The fold difference, as a pure number rounded to three significant figures.\n\nStep 2: Validation\nThe problem is scientifically grounded, as the Plaque Reduction Neutralization Test ($\\text{PRNT}$) is a standard and fundamental assay in virology and immunology. All definitions provided—plaque reduction, dilution factor, and titer—are correct and conform to established laboratory practice. The problem is well-posed, providing all necessary information and clear definitions to arrive at a unique, stable solution. The language is objective and technical. The data provided ($1{:}320$ and $1{:}40$ dilutions) are realistic for such assays. The problem has no internal contradictions, ambiguities, or logical flaws.\n\nStep 3: Verdict\nThe problem is valid. A complete solution will be provided.\n\nThe problem requires a step-by-step application of the provided definitions.\n\n(i) Determination of the $\\text{PRNT}_{50}$ Titer for Serum A.\nThe $\\text{PRNT}_{50}$ titer is defined as the reciprocal of the dilution factor, $d$, at which a $50\\%$ plaque reduction is observed. A $50\\%$ reduction corresponds to a fractional reduction $R(d) = 0.5$.\nFor Serum A, this condition is met at a dilution of $1{:}320$. The corresponding dilution factor, $d_A$, is the fractional representation of this dilution:\n$$d_A = \\frac{1}{320}$$\nAccording to the definition, the $\\text{PRNT}_{50}$ titer for Serum A, which we denote as $\\text{Titer}_A$, is the reciprocal of $d_A$:\n$$\\text{Titer}_A = \\frac{1}{d_A} = \\frac{1}{\\frac{1}{320}} = 320$$\n\n(ii) Derivation of Method for Comparing Neutralizing Activity.\nNeutralization potency refers to the effectiveness of a serum in neutralizing a pathogen. A higher potency implies that a smaller amount of the original serum is required to achieve a specific level of neutralization. In the context of the $\\text{PRNT}$ assay, this means a more potent serum must be diluted to a greater extent to reduce its neutralizing activity to the $50\\%$ threshold.\nLet us consider two sera, Serum A and Serum B, with corresponding dilution factors $d_A$ and $d_B$ that each yield $R(d) = 0.5$. Their respective titers are $\\text{Titer}_A = \\frac{1}{d_A}$ and $\\text{Titer}_B = \\frac{1}{d_B}$.\nIf Serum A is more potent than Serum B, it means that to reach the same $50\\%$ neutralization endpoint, Serum A must be diluted more than Serum B. A greater dilution corresponds to a smaller dilution factor. Therefore, if Serum A is more potent than Serum B, then $d_A  d_B$.\nFrom this inequality, we can deduce the relationship between their titers:\n$$d_A  d_B \\implies \\frac{1}{d_A}  \\frac{1}{d_B} \\implies \\text{Titer}_A  \\text{Titer}_B$$\nThis shows that a higher $\\text{PRNT}_{50}$ titer corresponds to a higher neutralization potency. The comparison of neutralizing activity between two sera can thus be formalized as the ratio of their titers. The fold difference in potency of Serum A relative to Serum B is given by the ratio:\n$$\\text{Fold Difference} = \\frac{\\text{Titer}_A}{\\text{Titer}_B}$$\nThis ratio quantifies how many times more potent Serum A is compared to Serum B.\n\n(iii) Computation of the Fold Difference.\nFollowing the logic established in parts (i) and (ii), we first calculate the titer for Serum B. Serum B achieves $R(d) = 0.5$ at a dilution of $1{:}40$. The dilution factor $d_B$ is:\n$$d_B = \\frac{1}{40}$$\nThe $\\text{PRNT}_{50}$ titer for Serum B, $\\text{Titer}_B$, is the reciprocal of $d_B$:\n$$\\text{Titer}_B = \\frac{1}{d_B} = \\frac{1}{\\frac{1}{40}} = 40$$\nWe have already determined that $\\text{Titer}_A = 320$. The fold difference in neutralization potency of Serum A relative to Serum B is the ratio of their titers:\n$$\\text{Fold Difference} = \\frac{\\text{Titer}_A}{\\text{Titer}_B} = \\frac{320}{40} = 8$$\nThe problem requires this result rounded to three significant figures. The exact value is $8$, which is written as $8.00$ to convey three significant figures. Serum A is therefore $8.00$ times more potent than Serum B.", "answer": "$$\\boxed{8.00}$$", "id": "2832663"}, {"introduction": "A quantitative result is only as meaningful as the experiment is clean. This problem challenges you to move beyond calculation and think like a critical experimentalist, diagnosing a potential artifact in a neutralization assay. By considering how a co-diluting decoy molecule can mimic the activity of a non-blocking antibody, you will practice dissecting confounding variables and appreciate the central role of proper controls in making valid scientific claims. [@problem_id:2832719]", "problem": "A laboratory evaluates a monoclonal antibody (mAb) against an enveloped virus that attaches to host cells via a single essential protein–protein interaction between the viral attachment protein and a host receptor. The mAb binds the viral attachment protein at an epitope that does not overlap the receptor-binding site and has been shown by structural studies to be non-blocking for receptor engagement. Neutralization is assessed with a virus–cell attachment assay performed at $4\\,^\\circ\\mathrm{C}$, in which virus is pre-incubated for $30$ minutes with serial dilutions of immune serum and then applied to receptor-positive target cells; after washing, cell-associated viral genomes are quantified by quantitative polymerase chain reaction (qPCR) and expressed as percent attachment relative to a no-antibody control. The no-antibody control is prepared in serum-free buffer, whereas each antibody dilution is prepared as a corresponding dilution of whole immune serum (i.e., higher antibody concentrations correspond to higher serum fractions). Unbeknownst to the investigators, the serum contains a soluble ectodomain of the viral receptor at concentration $\\rho$ in neat serum, which can bind the virion with dissociation constant $K_{D,VR_s}$ and act as a decoy. Assume classical mass-action binding equilibria, that the number of virions is much smaller than the number of receptor molecules (both soluble and on the cell), and that the mAb is genuinely non-blocking for receptor engagement and does not change the virion’s capacity to bind receptor other than via forming immune complexes.\n\nUsing only mass-action binding and the definition that “attachment” in this assay is proportional to the concentration of virions that arrive at the cell surface unbound by soluble receptor decoys, analyze whether and how soluble receptor decoys in serum can artifactually inflate apparent neutralization for this non-blocking mAb when antibody titrations are performed as serial dilutions of whole serum. Then, choose the single best experimental control that would most directly detect and attribute any apparent neutralization to soluble receptor decoys rather than to the antibody.\n\n- A. Protein G purification of immunoglobulin G (IgG) from immune serum followed by testing the same IgG mass in serum-free buffer, with a rescue condition in which recombinant soluble receptor ectodomain is added back at a defined concentration; loss of “neutralization” with purified IgG alone and its restoration upon ectodomain add-back would implicate receptor decoys.\n- B. Heat-inactivation of serum at $56\\,^\\circ\\mathrm{C}$ for $30$ minutes before the attachment assay to abolish complement activity; persistence of “neutralization” after heat-inactivation would confirm antibody-mediated neutralization.\n- C. Performing the attachment assay on Fragment crystallizable gamma receptor (Fc$\\gamma$R)-deficient target cells to exclude Fc receptor contributions to apparent neutralization at $4\\,^\\circ\\mathrm{C}$.\n- D. Increasing the multiplicity of infection (MOI) by $10$-fold in all conditions to overcome weak decoy effects; if “neutralization” persists, it must be antibody-mediated.\n\nYour analysis should start from mass-action equilibrium for virion–soluble receptor binding, treat the serum dilution factor $s \\in (0,1]$ as scaling the soluble receptor concentration $[R_s] = s \\rho$, and consider that, for a non-blocking mAb, cell attachment depends on the fraction of virions not engaged by $R_s$ rather than on $[A]$ per se. Do not assume any specific numerical values for $\\rho$ or $K_{D,VR_s}$ beyond being in a physiologically plausible range (e.g., nanomolar). Conclude with the single best control from the options above that would most directly detect and attribute an artifactual effect to soluble receptor decoys.", "solution": "The problem statement describes a scenario in which an immunological assay may be subject to a confounding variable, leading to a misinterpretation of experimental results. The task is to first provide a theoretical analysis of this artifact and then to identify the most appropriate experimental control to diagnose and attribute the artifact.\n\n### Problem Validation\nFirst, the problem statement must be validated for correctness and coherence.\n\n*   **Givens:**\n    *   A non-blocking monoclonal antibody (mAb) is tested against an enveloped virus.\n    *   The assay measures virus-cell attachment at $4\\,^\\circ\\mathrm{C}$ after pre-incubation of virus with serially diluted immune serum.\n    *   The readout is percent attachment relative to a no-antibody control (prepared in serum-free buffer).\n    *   Higher antibody concentrations are achieved by using higher fractions of whole immune serum.\n    *   The immune serum contains a soluble viral receptor ectodomain ($R_s$) at a concentration of $\\rho$ in neat serum, which acts as a decoy with dissociation constant $K_{D,VR_s}$.\n    *   The number of virions is much less than the number of receptor molecules.\n    *   \"Attachment\" is proportional to the concentration of virions not bound by soluble receptor decoys.\n    *   The mAb is genuinely non-blocking.\n\n*   **Validation:**\n    *   **Scientific Grounding:** The problem is scientifically sound. It is based on established principles of virology, immunology, and biophysical chemistry, including mass-action kinetics, antibody function, and receptor-decoy mechanisms. The scenario of a soluble receptor in serum acting as a confounder is a realistic and important consideration in experimental design.\n    *   **Well-Posedness:** The problem is well-posed. It presents a clear scenario and asks for a specific analysis and the evaluation of defined experimental controls. A unique, logical solution can be derived from the information provided.\n    *   **Objectivity:** The problem is stated in objective, technical language, free from ambiguity or subjective claims.\n    *   **Consistency and Completeness:** The problem is self-contained and internally consistent. It provides all necessary definitions (e.g., the basis of \"attachment\") and constraints to perform the required analysis.\n\n*   **Verdict:** The problem statement is valid. It presents a rigorous and conceptually sound challenge in experimental design and data interpretation.\n\n### Analysis of the Artifactual Neutralization\n\nThe analysis will demonstrate how the presence of a soluble receptor decoy ($R_s$) that co-dilutes with the antibody ($A$) can create an artificial neutralization curve.\n\nLet $[V]$ be the concentration of free virions, $[R_s]$ be the concentration of the soluble receptor decoy, and $[VR_s]$ be the concentration of the virion-decoy complex. The binding equilibrium is given by:\n$$V + R_s \\rightleftharpoons VR_s$$\n\nThe dissociation constant, $K_{D,VR_s}$, for this interaction is:\n$$K_{D,VR_s} = \\frac{[V][R_s]}{[VR_s]}$$\n\nThe total concentration of virions, $[V]_{total}$, is the sum of free and bound virions:\n$$[V]_{total} = [V] + [VR_s]$$\n\nThe problem states that attachment is proportional to the concentration of virions that are not bound by the soluble decoys. This corresponds to the fraction of unbound virions, $f_{unbound}$:\n$$f_{unbound} = \\frac{[V]}{[V]_{total}} = \\frac{[V]}{[V] + [VR_s]}$$\n\nFrom the definition of $K_{D,VR_s}$, we can express $[VR_s]$ as $[VR_s] = \\frac{[V][R_s]}{K_{D,VR_s}}$. Substituting this into the equation for $f_{unbound}$:\n$$f_{unbound} = \\frac{[V]}{[V] + \\frac{[V][R_s]}{K_{D,VR_s}}} = \\frac{1}{1 + \\frac{[R_s]}{K_{D,VR_s}}}$$\n\nThe problem specifies that the serum dilutions are made from whole serum. Let $s$ be the serum dilution factor, where $s \\in (0, 1]$. $s=1$ corresponds to neat serum, and $s \\to 0$ corresponds to infinite dilution. The concentration of the soluble receptor in the assay is $[R_s] = s \\rho$, where $\\rho$ is the concentration in neat serum. We can substitute this into the expression for $f_{unbound}$:\n$$f_{unbound}(s) = \\frac{1}{1 + \\frac{s\\rho}{K_{D,VR_s}}}$$\n\nIn the experiment, a \"neutralization\" curve is generated by plotting percent attachment against the antibody concentration, $[A]$. Since the antibody is in the serum, its concentration is also proportional to the serum dilution factor $s$. Let $[A]_{neat}$ be the mAb concentration in neat serum, so $[A] = s [A]_{neat}$. Therefore, high antibody concentration corresponds to a high value of $s$, and low antibody concentration corresponds to a low value of $s$.\n\nAnalyzing the function $f_{unbound}(s)$:\n*   At high antibody concentrations (high $s$, approaching $1$), the term $\\frac{s\\rho}{K_{D,VR_s}}$ is maximal. This results in a minimal value for $f_{unbound}$, leading to low measured attachment.\n*   At low antibody concentrations (low $s$, approaching $0$), the term $\\frac{s\\rho}{K_{D,VR_s}}$ approaches $0$. This results in $f_{unbound}$ approaching $1$, leading to high measured attachment.\n\nThis inverse relationship between antibody concentration and viral attachment is precisely what defines a neutralization curve. However, in this case, the effect is not mediated by the antibody (which is stipulated to be non-blocking) but by the co-diluted soluble receptor decoy. The experimental design has created a perfect confound where the concentration of the causative agent ($[R_s]$) is directly proportional to the tested variable ($[A]$), leading to an artifactual \"neutralization\" effect.\n\n### Evaluation of Experimental Controls\n\nThe goal is to select the single best control that can both detect this artifact and correctly attribute it to the soluble receptor decoy.\n\n*   **A. Protein G purification of immunoglobulin G (IgG) from immune serum followed by testing the same IgG mass in serum-free buffer, with a rescue condition in which recombinant soluble receptor ectodomain is added back at a defined concentration; loss of “neutralization” with purified IgG alone and its restoration upon ectodomain add-back would implicate receptor decoys.**\n    This proposed control is a rigorous, multi-step experiment designed to isolate variables.\n    1.  **Purification:** Protein G selectively binds the Fc region of IgG, allowing for the separation of antibodies from other serum proteins, including the soluble receptor decoy $R_s$.\n    2.  **Testing Purified IgG:** Re-running the titration with purified IgG in a clean, serum-free buffer removes the confounding variable ($R_s$). Given that the mAb is non-blocking, we predict that the \"neutralization\" effect will disappear. This step serves to **detect** that the effect observed with whole serum was not intrinsic to the antibody itself.\n    3.  **Add-back (Rescue):** Adding a known quantity of recombinant soluble receptor back to the purified IgG preparation and observing a restoration of the \"neutralization\" curve directly tests the hypothesis that $R_s$ was the causative agent. This step serves to **attribute** the effect.\n    This comprehensive approach provides the necessary evidence to both identify the artifact and determine its cause.\n    **Verdict: Correct.**\n\n*   **B. Heat-inactivation of serum at $56\\,^\\circ\\mathrm{C}$ for $30$ minutes before the attachment assay to abolish complement activity; persistence of “neutralization” after heat-inactivation would confirm antibody-mediated neutralization.**\n    Heat inactivation is a standard method to eliminate complement activity. While complement can mediate neutralization, it is not the confounder described in the problem setup. The primary confounder is the soluble receptor decoy, $R_s$. The thermal stability of $R_s$ is unknown. If $R_s$ is stable at $56\\,^\\circ\\mathrm{C}$ (which many proteins are), the artifactual neutralization will persist. The conclusion stated in the option—\"would confirm antibody-mediated neutralization\"—is a logical fallacy (a non-sequitur). The persistence of the effect could be due to the heat-stable decoy receptor, not the antibody. Therefore, this control fails to properly dissect the mechanism.\n    **Verdict: Incorrect.**\n\n*   **C. Performing the attachment assay on Fragment crystallizable gamma receptor (Fc$\\gamma$R)-deficient target cells to exclude Fc receptor contributions to apparent neutralization at $4\\,^\\circ\\mathrm{C}$.**\n    Fc$\\gamma$Rs on target cells bind the Fc region of antibodies. If these receptors were to play a role, they would likely bind antibody-opsonized virions, potentially *increasing* the amount of virus associated with the cells. This phenomenon, antibody-dependent enhancement (ADE), is the opposite of neutralization. Thus, Fc$\\gamma$Rs are not a plausible cause for the observed *decrease* in attachment. Furthermore, active cellular processes like phagocytosis via Fc$\\gamma$Rs are inhibited at $4\\,^\\circ\\mathrm{C}$. This control addresses a mechanism that is irrelevant to the artifact described.\n    **Verdict: Incorrect.**\n\n*   **D. Increasing the multiplicity of infection (MOI) by $10$-fold in all conditions to overcome weak decoy effects; if “neutralization” persists, it must be antibody-mediated.**\n    Increasing the MOI means increasing the total concentration of virions, $[V]_{total}$. The soluble decoy receptor is present at a fixed concentration, $[R_s]_T = s\\rho$, for any given serum dilution. If $[V]_{total}$ is substantially increased to a level where it is no longer negligible compared to $[R_s]_T$, the decoys can become saturated. This would make the decoy less effective on a per-virion basis, thus weakening the apparent neutralization (i.e., shifting the curve to the right). However, the effect would still persist as long as $[R_s]_T$ is not zero. The conclusion, \"if 'neutralization' persists, it must be antibody-mediated,\" is again a flawed inference. The decoy-mediated effect would also persist, just in a weakened form. This experiment does not provide a clean distinction between the antibody's effect and the decoy's effect.\n    **Verdict: Incorrect.**\n\n### Conclusion\n\nOption A provides the most direct and scientifically rigorous method to both detect the experimental artifact and attribute it correctly to the soluble receptor decoy. It achieves this by physically separating the antibody from the confounding serum components and then systematically testing their effects in isolation and in combination. This represents the gold standard for elucidating the roles of individual components in a complex biological system.", "answer": "$$\\boxed{A}$$", "id": "2832719"}, {"introduction": "To truly understand neutralization, we must connect macroscopic observations to the underlying molecular interactions. This practice bridges this gap by modeling neutralization as a competitive binding process governed by mass-action principles. By calculating the antibody concentration required to outcompete a host receptor for binding to a virus and achieve a specified level of inhibition, you will gain a quantitative appreciation for how antibody affinity ($K_{A}$) and receptor affinity ($K_{R}$) dictate a neutralizing antibody's efficacy. [@problem_id:2832726]", "problem": "A spherical target cell displays a host receptor used by a virus for attachment. The virus can also be bound by a neutralizing monoclonal antibody that competes for the same viral epitope required for receptor engagement. Assume the following:\n- The receptor copy number per cell is $N_{R} = 10^{5}$, uniformly distributed on the cell surface.\n- The cell is a sphere of radius $r = 10\\,\\mu\\mathrm{m}$.\n- The receptor is treated as an effective three-dimensional competitor within a thin capture shell of thickness $\\delta = 10\\,\\mathrm{nm}$, so that the effective receptor concentration is computed using the shell volume $V_{\\mathrm{shell}} = 4\\pi r^{2}\\delta$.\n- The equilibrium dissociation constant (KD) for virion–receptor binding is $K_{R} = 10\\,\\mathrm{nM}$.\n- The equilibrium dissociation constant (KD) for virion–antibody binding is $K_{A} = 100\\,\\mathrm{pM}$.\n- Binding is $1{:}1$ for each ligand to a single viral epitope, mass-action equilibrium holds, receptor and antibody compete exclusively for the same viral site, and ligand depletion is negligible (free concentrations equal total concentrations).\n- Use the Avogadro constant $N_{A} = 6.022\\times 10^{23}\\,\\mathrm{mol}^{-1}$ and the conversion $1\\,\\mathrm{m}^{3} = 10^{3}\\,\\mathrm{L}$.\n\nUsing mass-action equilibrium and competitive binding logic, compute the total antibody concentration required to reduce the probability of receptor-mediated attachment by $90\\%$ relative to the no-antibody baseline. Express your final answer in micromolar and round to three significant figures.", "solution": "The problem statement is validated as scientifically grounded, well-posed, and objective. It presents a standard competitive binding scenario from quantitative immunology and provides all necessary parameters and constants for a unique solution. We shall proceed with the derivation.\n\nLet $V$ represent the virus, $R$ the host cell receptor, and $A$ the neutralizing monoclonal antibody. The system is governed by two simultaneous competitive binding equilibria, which follow the law of mass action:\n$V + R \\rightleftharpoons VR$ with an equilibrium dissociation constant $K_R = \\frac{[V][R]}{[VR]}$.\n$V + A \\rightleftharpoons VA$ with an equilibrium dissociation constant $K_A = \\frac{[V][A]}{[VA]}$.\n\nHere, $[V]$, $[R]$, and $[A]$ are the molar concentrations of free virus, receptor, and antibody, respectively. $[VR]$ and $[VA]$ are the concentrations of the virus-receptor and virus-antibody complexes. The problem states that ligand depletion is negligible, so the free concentrations of receptor and antibody can be approximated by their total effective concentrations.\n\nThe probability of a virus particle attaching to a receptor is proportional to the fraction of viral particles that are bound to receptors. This fraction, which we denote as $\\theta_{VR}$, is the concentration of virus-receptor complexes divided by the total concentration of virus particles in all states (free, receptor-bound, and antibody-bound).\nThe total concentration of virus is $[V]_{\\mathrm{total}} = [V] + [VR] + [VA]$.\nUsing the equilibrium constant definitions, we can express $[VR]$ and $[VA]$ in terms of the free virus concentration $[V]$:\n$[VR] = \\frac{[V][R]}{K_{R}}$\n$[VA] = \\frac{[V][A]}{K_{A}}$\nSubstituting these into the expression for $[V]_{\\mathrm{total}}$ gives:\n$$[V]_{\\mathrm{total}} = [V] + \\frac{[V][R]}{K_{R}} + \\frac{[V][A]}{K_{A}} = [V] \\left( 1 + \\frac{[R]}{K_{R}} + \\frac{[A]}{K_{A}} \\right)$$\nThe fraction of virus bound to receptor is therefore:\n$$\\theta_{VR} = \\frac{[VR]}{[V]_{\\mathrm{total}}} = \\frac{\\frac{[V][R]}{K_{R}}}{[V] \\left( 1 + \\frac{[R]}{K_{R}} + \\frac{[A]}{K_{A}} \\right)} = \\frac{\\frac{[R]}{K_{R}}}{1 + \\frac{[R]}{K_{R}} + \\frac{[A]}{K_{A}}}$$\nIn the absence of antibody, $[A]=0$, the baseline fraction of receptor-bound virus, $\\theta_{VR,0}$, is:\n$$\\theta_{VR,0} = \\frac{\\frac{[R]}{K_{R}}}{1 + \\frac{[R]}{K_{R}}}$$\nThe objective is to find the antibody concentration $[A]$ that reduces the probability of receptor-mediated attachment by $90\\%$. This translates to the condition that the new fractional occupancy $\\theta_{VR}$ must be $10\\%$ of the baseline occupancy $\\theta_{VR,0}$:\n$$\\theta_{VR} = (1 - 0.9) \\theta_{VR,0} = 0.1 \\times \\theta_{VR,0}$$\nSubstituting the expressions for $\\theta_{VR}$ and $\\theta_{VR,0}$ yields the governing equation:\n$$\\frac{\\frac{[R]}{K_{R}}}{1 + \\frac{[R]}{K_{R}} + \\frac{[A]}{K_{A}}} = 0.1 \\times \\frac{\\frac{[R]}{K_{R}}}{1 + \\frac{[R]}{K_{R}}}$$\nAs the receptor concentration $[R]$ is non-zero, the term $\\frac{[R]}{K_{R}}$ can be canceled from both numerators:\n$$\\frac{1}{1 + \\frac{[R]}{K_{R}} + \\frac{[A]}{K_{A}}} = \\frac{0.1}{1 + \\frac{[R]}{K_{R}}}$$\nWe now rearrange this equation to solve for $[A]$:\n$$1 + \\frac{[R]}{K_{R}} = 0.1 \\left( 1 + \\frac{[R]}{K_{R}} + \\frac{[A]}{K_{A}} \\right)$$\n$$10 \\left( 1 + \\frac{[R]}{K_{R}} \\right) = 1 + \\frac{[R]}{K_{R}} + \\frac{[A]}{K_{A}}$$\n$$9 \\left( 1 + \\frac{[R]}{K_{R}} \\right) = \\frac{[A]}{K_{A}}$$\n$$[A] = 9 K_{A} \\left( 1 + \\frac{[R]}{K_{R}} \\right)$$\nThis is the required expression. To obtain a numerical value, we must first calculate the effective receptor concentration $[R]$. The number of receptors is $N_{R} = 10^{5}$, distributed in a shell volume $V_{\\mathrm{shell}} = 4\\pi r^{2}\\delta$ around a cell of radius $r=10\\,\\mu\\mathrm{m}$ with shell thickness $\\delta=10\\,\\mathrm{nm}$.\nFirst, we express radius and thickness in SI units ($m$):\n$r = 10\\,\\mu\\mathrm{m} = 10 \\times 10^{-6}\\,\\mathrm{m} = 10^{-5}\\,\\mathrm{m}$\n$\\delta = 10\\,\\mathrm{nm} = 10 \\times 10^{-9}\\,\\mathrm{m} = 10^{-8}\\,\\mathrm{m}$\nThe shell volume is:\n$$V_{\\mathrm{shell}} = 4\\pi (10^{-5}\\,\\mathrm{m})^{2} (10^{-8}\\,\\mathrm{m}) = 4\\pi \\times 10^{-18}\\,\\mathrm{m}^3$$\nTo calculate molar concentration, we convert this volume to liters ($1\\,\\mathrm{m}^{3} = 10^{3}\\,\\mathrm{L}$):\n$$V_{\\mathrm{shell}} = 4\\pi \\times 10^{-18}\\,\\mathrm{m}^3 \\times \\frac{10^3\\,\\mathrm{L}}{1\\,\\mathrm{m}^3} = 4\\pi \\times 10^{-15}\\,\\mathrm{L}$$\nThe molar concentration $[R]$ is the number of moles of receptors, $n_{R} = N_{R}/N_{A}$, per unit volume:\n$$[R] = \\frac{N_{R}}{N_{A} V_{\\mathrm{shell}}} = \\frac{10^{5}}{(6.022\\times 10^{23}\\,\\mathrm{mol}^{-1}) (4\\pi \\times 10^{-15}\\,\\mathrm{L})}$$\n$$[R] = \\frac{10^{5 + 15}}{4\\pi \\times 6.022 \\times 10^{23}}\\,\\mathrm{M} = \\frac{10^{20}}{75.666 \\times 10^{23}}\\,\\mathrm{M} \\approx 1.3216 \\times 10^{-5}\\,\\mathrm{M}$$\nWe are given the dissociation constants:\n$K_{R} = 10\\,\\mathrm{nM} = 10 \\times 10^{-9}\\,\\mathrm{M} = 10^{-8}\\,\\mathrm{M}$\n$K_{A} = 100\\,\\mathrm{pM} = 100 \\times 10^{-12}\\,\\mathrm{M} = 10^{-10}\\,\\mathrm{M}$\nNow, we substitute all numerical values into the derived equation for $[A]$:\n$$[A] = 9 \\times (10^{-10}\\,\\mathrm{M}) \\times \\left( 1 + \\frac{1.3216 \\times 10^{-5}\\,\\mathrm{M}}{10^{-8}\\,\\mathrm{M}} \\right)$$\nThe dimensionless ratio is:\n$$\\frac{[R]}{K_{R}} = \\frac{1.3216 \\times 10^{-5}}{10^{-8}} = 1321.6$$\nSo the equation becomes:\n$$[A] = 9 \\times 10^{-10} \\times (1 + 1321.6)\\,\\mathrm{M}$$\n$$[A] = 9 \\times 10^{-10} \\times 1322.6\\,\\mathrm{M}$$\n$$[A] = 11903.4 \\times 10^{-10}\\,\\mathrm{M} = 1.19034 \\times 10^{-6}\\,\\mathrm{M}$$\nThe result is required in micromolar ($1\\,\\mu\\mathrm{M} = 10^{-6}\\,\\mathrm{M}$):\n$$[A] = 1.19034\\,\\mu\\mathrm{M}$$\nRounding to three significant figures, the final concentration is $1.19\\,\\mu\\mathrm{M}$.", "answer": "$$\\boxed{1.19}$$", "id": "2832726"}]}